Teva scientists have been conducting innovative research and developing new treatments for over two decades. Our researchers are recognized leaders in combating neurological disorders and providing respiratory therapy. Teva scientists are also doing cutting edge work in the areas of oncology, Alzheimer’s disease, stroke, epilepsy, pulmonary medicine, endocrinology and others. Some of Teva’s innovative products include:

Multiple Sclerosis – COPAXONE® (glatiramer acetate injection) is indicated for the reduction of the frequency of relapses in relapsing-remitting multiple sclerosis.

      Important Safety Information

• The most common side effects of COPAXONE® are redness, pain, swelling, itching, or a lump at the site of injection, flushing, chest pain, weakness, infection, pain, nausea, joint pain, anxiety, and muscle stiffness. These reactions are usually mild and seldom require professional treatment. Patients should tell their doctor about any side effects.
• Some patients report a short-term reaction right after injecting COPAXONE®. This reaction can involve flushing (feeling of warmth and/or redness), chest tightness or pain with heart palpitations, anxiety, and trouble breathing. These symptoms generally appear within minutes of an injection, last about 15 minutes, and go away by themselves without further problems.
• A permanent indentation under the skin at the injection site may occur, due to a local destruction of fat tissue. Patients should follow proper injection technique and inform their doctor of any skin changes.
• After injecting COPAXONE®, patients should call their doctor right away if they develop hives, skin rash with irritation, dizziness, sweating, chest pain, trouble breathing, severe pain at the injection site or other uncomfortable changes in their general health. Patients should not give themselves any more injections until their doctor tells them to begin again.

      Please click here for Copaxone Prescribing Information

Parkinson’s Disease – AZILECT® (rasagiline tablets) is indicated for the treatment of the signs and symptoms of Parkinson’s disease (PD) both as initial therapy alone and to be added to levodopa later in the disease. The effectiveness of AZILECT was shown in patients with early PD who were receiving AZILECT as initial therapy alone and who were not receiving any other PD therapy. The effectiveness of AZILECT as adjunct therapy was shown in patients with PD who were treated with levodopa.

      Important Safety Information

• Patients should not take AZILECT if they are currently taking meperidine as it could possibly result in a serious reaction such as coma or death.
• Patients should not take AZILECT with tramadol, methadone, propoxyphene, dextromethorphan, St. John’s wort, mirtazapine, or cyclobenzaprine.
• Patients should not take AZILECT with other monoamine oxidase inhibitors (MAOIs), amphetamines, cold remedies containing decongestants and weight-reducing preparations containing pseudoephedrine, phenylephrine, phenylpropanolamine, or ephedrine in order to avoid a possibly dangerous increase in blood pressure. Symptoms of this reaction include severe headache, blurred vision, difficulty thinking, seizures, chest pain, unexplained nausea or vomiting, or signs or symptoms of a stroke. Patients or caregivers should seek immediate medical attention if these symptoms or other unusual symptoms occur.
• In order to prevent a possibly dangerous increase in blood pressure, patients taking AZILECT should avoid foods and beverages high in tyramine content such as aged cheeses, air-dried meats, pickled herring, yeast extract, aged red wines, tap/draft beers, sauerkraut, and soy sauce.
• Patients taking AZILECT should not have elective surgery requiring general anesthesia, and should not receive cocaine or other local anesthesia that contains ingredients that could raise blood pressure.
• Patients should inform their physician if they are taking, or planning to take, any prescription or over-the-counter drugs, especially antidepressants and ciprofloxacin.
• Patients with moderate to severe liver disease or a tumor of the adrenal gland should not take AZILECT.
• All PD patients are advised to monitor for melanoma (skin cancer) frequently and see a dermatologist on a regular basis.
• Side effects seen with AZILECT alone are headache, joint pain and indigestion; and when taken with levodopa are uncontrolled movements (dyskinesias), accidental injury, nausea, weight loss, constipation, low blood pressure when standing, joint pain, vomiting, dry mouth, rash, and sleepiness. Patients should tell their doctor about these and any other side effects they experience when taking AZILECT.

      Please click here for Azilect Prescribing Information

Respiratory Disease – ProAir® HFA (albuterol sulfate) Inhalation Aerosol is indicated in patients 4 years of age and older for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm.

      Important Safety Information

• If your symptoms become significantly worse when you use ProAir® HFA, contact your doctor immediately. This may indicate either a worsening of your asthma or a reaction to the medication, which may rarely occur with the first use of a new canister of ProAir® HFA. Either of these could be life-threatening.
• What to tell your doctor before using ProAir® HFA: If you have a heart, blood, or seizure disorder, high blood pressure, diabetes, or an overactive thyroid, be sure to tell your doctor. Also make sure your doctor knows all medications you are taking – especially heart medications and drugs that treat depression – because some medications may interfere with how well your asthma medications work. Do not exceed the recommended dose.
• Side effects associated with ProAir® HFA included headache, rapid heart beat, pain, dizziness, and irritation of the throat and nose.

      Please click here for ProAir® HFA Prescribing Information

QVAR® (beclomethasone diproprionate HFA) Inhalation Aerosol is indicated in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age or older. QVAR® is also indicated for asthma patients who require systemic corticosteroid administration, where adding QVAR® may reduce or eliminate the need for systemic corticosteroids.

      Important Safety Information

• QVAR® does not replace fast-acting (rescue) inhalers for sudden symptoms.
• If you are switching from an oral corticosteroid to QVAR®, follow your doctor’s instructions to avoid health risks when you stop using oral corticosteroids.
• Inhaled corticosteroids may cause a reduction in growth rate. The long-term effect on final adult growth is unknown.
• In clinical studies, common side effects included headache and pharyngitis.
• Do not stop taking QVAR® abruptly without talking to your doctor.

      Please click here for QVAR Prescribing Information

Growth Hormone Deficiency – TEV-TROPIN® [somatropin (rDNA origin) for injection] is indicated for the treatment of children who have growth failure due to growth hormone deficiency (GHD).

      Important Safety Information

• Growth hormone may be used in children with confirmed Prader-Willi Syndrome only when diagnosed with GHD. Children who are severely overweight, have breathing problems while awake or asleep, and have lung infections should stop use of growth hormone and consult a physician. This may occur more in boys.
• Changes in eyesight, headaches, nausea, and vomiting may occur. Frequent eye examinations should be done before and during treatment. Patients should be observed for elevated blood glucose, underactive thyroid, underactive pituitary, skin cancers, development of a limp, or complaint of hip or knee pain. Patients with rapid onset critical illness as a result of open heart or abdominal surgery, multiple accidental trauma, or rapid onset respiratory failure should not be started on TEV-TROPIN®. Patients with injury or active cancer in the brain, eye problems related to diabetes, or bones that have stopped growing should not receive recombinant growth hormone.
• When TEV-TROPIN® is administered at the same site over a long period of time, damage to the tissue may result. This can be avoided by rotating the injection site.
• Because TEV-TROPIN® increases growth rate, patients with a history of curvature of the spine (scoliosis) should be monitored.
• TEV-TROPIN® may interfere with other drugs removed from the body by the liver and careful monitoring is advisable.
• The liquid provided to mix TEV-TROPIN® should not be used in newborns because of associated toxicity. Doses of reconstituted TEV-TROPIN® greater than 1 mL are not recommended. Consult your child’s physician for doses greater than 1 mL. Do not exceed the dose recommended by your child’s physician.
• In studies of GHD children, headaches occurred infrequently. Injection-site reactions, for instance pain or bruising, occurred in 8 of the 164 treated patients.

      Please click here for Tev-Tropin Prescribing Information

COPAXONE® and AZILECT® are registered trademarks of Teva Pharmaceuticals Ltd. ProAir® HFA is a registered trademark of Teva Specialty Pharmaceuticals LLC. QVAR® is a registered trademark of IVAX Corporation, a member of the Teva Group. TEV-TROPIN® is a registered trademark of Teva Pharmaceuticals USA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.